Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry.
Maria ChaparroAna GarreMarisa IborraMónica Sierra-AusínManuel Barreiro-de AcostaAgnès Fernández-ClotetLuisa de CastroMaia Boscá-WattsMaría José CasanovaAlicia López-GarcíaRufo LorenteCristina RodríguezAna Y CarbajoMaria Teresa ArroyoAna GutiérrezJoaquín HinojosaTeresa Martínez-PérezAlbert VilloriaFernando BermejoDavid BusquetsBlau CampsFiorella CañeteNoemí ManceñidoDavid MonfortMercè Navarro-LlavatJosé Lázaro Pérez-CalleLaura RamosMontserrat RiveroTeresa AngueiraPatricia Camo MonterdeDaniel CarpioIrene García-de-la-FiliaCarlos González-MuñozaLuis HernándezJosé M HuguetVíctor Jair Morales-AlvaradoBeatriz SiciliaPablo VegaIsabel VeraYamile ZabanaPilar NosPatricia Suárez ÁlvarezCristina Calviño-SuárezElena RicartVicent HernándezMiguel MínguezLucía MárquezDaniel Hervías CruzSaioa Rubio IturriaJesús BarrioCarla Gargallo-PuyueloRubén FrancésEsther HinojosaMaría Del MoralXavier CalvetAlicia AlgabaXavier AldeguerJordi GuardiolaMiriam MañosaRamón PajaresMarta PiquerasOrlando García-BoschPilar López SerranoBeatriz CastroAlfredo J LucendoMiguel MontoroElena Castro OrtizFrancisco MesoneroEsther García-PlanellaDavid A FuentesInmaculada BortPedro Delgado-GuillenaLara AriasAgueda IglesiasMarta CalvoMaria EsteveEugeni DomènechJavier P GisbertPublished in: Journal of Crohn's & colitis (2021)
Ustekinumab is effective in both the short and the long term in real life, even in a highly refractory cohort. Higher inflammatory burden at baseline correlated with lower probability of achieving remission. Safety was consistent with the known profile of ustekinumab.